Who
Michael Powell
Director
Company insider
Files Form 4 as: Director, Bicara Therapeutics; Director and 10% owner, Galera Therapeutics; Director and 10% owner, Checkmate Pharmaceuticals; 10% owner, Vera Therapeutics; 10% owner, Iterum Therapeutics; Director and 10% owner, Synlogic; 10% owner, Entasis Therapeutics Holdings; Director, Ocera Therapeutics.
In numbers
- Trades disclosed
- 190
- Buys
- 8
- Sells
- 25
- Bought
- $40.6M
- Sold
- $84.1M
- Companies
- 14
- Companies where not an officer
- 14
- First trade
- 15 Dec 2005
- Last trade
- 9 Jun 2026
- Last filed
- 10 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 9 Jun 2026filed 10 Jun 2026 | BCAX Bicara Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —19,475 at $0.00 | filing |
| 9 Jun 2026filed 10 Jun 2026 | BCAX Bicara Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —19,475 at $0.00 | filing |
| 9 Jun 2025filed 10 Jun 2025 | BCAX Bicara Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —23,746 at $0.00 | filing |
| 14 Jun 2023filed 16 Jun 2023 | Galera Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —64,000 at $0.00 | filing |
| 15 Jun 2022filed 16 Jun 2022 | Galera Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
| 31 May 2022filed 31 May 2022 | Checkmate Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —30,000 | filing |
| 31 May 2022filed 31 May 2022 | Checkmate Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —10,030 | filing |
| 31 May 2022filed 31 May 2022 | Checkmate Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —30,000 | filing |
| 9 Aug 2021filed 10 Aug 2021 | Checkmate Pharmaceuticalsoption or derivative | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 16 Jun 2021filed 21 Jun 2021 | Checkmate Pharmaceuticalsoption or derivative | SEC FORM 4 Code A | —10,030 at $0.00 | filing |
| 16 Jun 2021filed 17 Jun 2021 | Galera Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —13,179 at $0.00 | filing |
| 18 May 2021filed 18 May 2021 | VERA Vera Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code C | —2,187,504 at $0.00 | filing |
| 18 May 2021filed 18 May 2021 | VERA Vera TherapeuticsBiotechnology | SEC FORM 4 Code C | —2,187,504 | filing |
| 18 May 2021filed 18 May 2021 | VERA Vera TherapeuticsBiotechnology | SEC FORM 4 Bought | $8.0M727,272 at $11.00 | filing |
| 10 Nov 2020filed 12 Nov 2020 | Checkmate Pharmaceuticalsoption or derivative | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 9 Jun 2020filed 10 Jun 2020 | Galera Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —13,179 at $0.00 | filing |
| 21 Jan 2020filed 23 Jan 2020 | Iterum Therapeuticsoption or derivative | SEC FORM 4 Code A | — | filing |
| 6 Nov 2019filed 8 Nov 2019 | Galera Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —19,776 at $0.00 | filing |
| 5 Jun 2019filed 7 Jun 2019 | Synlogicoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 28 Sep 2018filed 2 Oct 2018 | Entasis Therapeutics Holdings | SEC FORM 4 Code C | —359,267 | filing |
News
No headline names them, or the companies they trade most, lately.